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Abstract GH and IGF-1 play an important role in the
regulation of metabolism and body composition. In patients
with uncontrolled acromegaly, cardiovascular morbidity
and mortality are increased but are supposed to be nor-
malised after biochemical control is achieved. We aimed at
comparing body composition and the cardiovascular risk
proﬁle in patients with controlled acromegaly and controls.
A cross-sectional study. We evaluated anthropometric
parameters (height, weight, body mass index (BMI), waist
and hip circumference, waist to height ratio) and, addi-
tionally, cardiovascular risk biomarkers (fasting plasma
glucose, HbA1c, triglycerides, total cholesterol, HDL,
LDL, and lipoprotein (a), in 81 acromegalic patients (58%
cured) compared to 320 age- and gender-matched controls
(ratio 1:4), sampled from the primary care patient cohort
DETECT. The whole group of 81 acromegalic patients
presented with signiﬁcantly higher anthropometric param-
eters, such as weight, BMI, waist and hip circumference,
but with more favourable cardiovascular risk biomarkers,
such as fasting plasma glucose, total cholesterol, triglyc-
erides and HDL levels, in comparison to their respective
controls. Biochemically controlled acromegalic patients
again showed signiﬁcantly higher measurements of obes-
ity, mainly visceral adiposity, than age- and gender-mat-
ched control patients (BMI 29.5 ± 5.9 vs. 27.3 ± 5.8 kg/
m
2; P = 0.020; waist circumference 100.9 ± 16.8 vs.
94.8 ± 15.5 cm; P = 0.031; hip circumference 110.7 ±
9.9 vs. 105.0 ± 11.7 cm; P = 0.001). No differences in the
classical cardiovascular biomarkers were detected except
for fasting plasma glucose and triglycerides. This effect
could not be attributed to a higher prevalence of type 2
diabetes mellitus in the acromegalic patient group, since
stratiﬁed analyses between the subgroup of patients with
acromegaly and controls, both with type 2 diabetes melli-
tus, revealed that there were no signiﬁcant differences in
the anthropometric measurements. Biochemically cured
acromegalic patients pertain an adverse anthropometric
risk proﬁle, mainly because of elevated adiposity mea-
surements, such as BMI, waist and hip circumference,
compared to an age- and gender-matched primary care
population.
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Introduction
Acromegaly, usually caused by a somatotroph pituitary
adenoma, is an endocrine disorder with an estimated
prevalence of 125 cases per million [1]. Due to the slowly
progressive nature of the disease, it often takes 6.6–
10.2 years until acromegaly is diagnosed [2]. Clinical
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comprises a broad spectrum of comorbidities, such as
cardiovascular features (i.e. hypertension), metabolic fea-
tures (i.e. diabetes mellitus), respiratory features (i.e. sleep
apnea), bone and joint features, soft tissue and skin chan-
ges, malignancies, endocrine consequences (thyroid goiter)
and a variety of neurological complications, such as nerve
compression syndromes [3]. Unless adequate biochemical
control is achieved, acromegaly is associated to elevated
morbidity and mortality, mostly because of cardiovascular
disease [4, 5].
Therapy for acromegaly represents a demanding task for
the physician, since a subset of patients exhibit treatment-
resistant disease. Management options include transsphe-
noidal surgery, representing the ﬁrst-line treatment for
acromegaly, radiation and medical therapy. Treatment with
somatostatin analogues inhibits GH secretion and induces
tumour shrinkage, whereas the GH receptor antagonist
pegvisomant effectively blocks GH action in the periphery
leading to disease control [6]. Effective control of GH and
IGF-1 excess improves comorbidities as well as lowers
mortality rates [7].
It is known that GH and IGF-1 play an important role in
the regulation of metabolism and body composition [8].
GH exhibits lipolytic effects and can cause insulin resis-
tance, whereas IGF-1 exhibits anti-lipolytic and insulin-
sensitising effects.
In acromegaly, an alteration of the body composition,
including an increase in body water and lean body mass
and a reduction in body fat, occurs.
Under therapy, and after the achievement of biochemi-
cal control, a reduction in body water and fat-free mass,
and an increase in body fat have been reported [9, 10].
However, it is not clear if this increase results in higher
adiposity measurements compared to a respective control
group.
Few studies have examined anthropometric and car-
diovascular risk parameters in patients with acromegaly
under therapy. Recently, Freda et al. reported a lower
visceral and subcutaneous fat mass in a cross-sectional
study with 24 adults with active acromegaly compared to
healthy controls. Sucunza et al. [8, 11] concluded from
their cross-sectional study in 60 acromegalic patients that
control of acromegaly reverts decreased fat mass.
Regarding cardiovascular risk parameters, a more athero-
genic lipoprotein proﬁle in active acromegalic patients,
consisting of higher levels of triglycerides and apolipo-
protein B, was reported in the study of Boero et al. [12]. In
another study, patients with active acromegaly presented
with a higher insulin resistance index and ﬁbrinogen levels
than patients and subjects in control groups; CRP, leuco-
cyte count, factor VIII and NT-pro BNP were similar in the
three groups [13].
The aim of our study was to evaluate the cardiovascular
risk proﬁle of ‘‘biochemically cured’’ acromegalic patients
by comparing their anthropometric parameters (height,
weight, body mass index (BMI), waist and hip circumfer-
ence, waist to height ratio), and cardiovascular risk bio-
markers, to an age- and gender-matched primary care
control group. Since acromegaly is associated with an
increased risk of diabetes mellitus, which might inﬂuence
the calculations, we performed stratiﬁed analyses in dia-
betic and non-diabetic patients separately.
Subjects and methods
Participants
Eighty-one patients with previously diagnosed acromegaly
were recruited at the Endocrine Outpatient Unit of the Max
PlanckInstituteofPsychiatry(MPIP)andtheDepartmentof
Internal Medicine, Ludwig-Maximilians-University (LMU)
in Munich. We sampled 320 age- and gender-matched
control subjects in a fasting state (ratio 1:4) from the
DETECT-cohort (Diabetes cardiovascular risk evaluation;
targets and essential data for commitment and treatment,
http://www.detect-studie.de/), a nationally representative
cohort of patients attending a primary care practice in
Germany [14, 15]. A 2 acromegalic patients had only two
adequate DETECT-matches, so that the control group
comprisedof320insteadof324subjects.Thecontrolgroups
for the subgroup analyses, as well as the diabetic control
group, were recruited from the same DETECT-cohort
(n = 320). All subjects gave their written informed consent.
The study was approved by the local ethical committee.
Diabetes cardiovascular risk-evaluation: targets and
essential data for commitment of treatment is a large,
multistage, cross-sectional study of 55,518 unselected
consecutive patients in 3,188 nationally representative
primary care ofﬁces in Germany with a laboratory and
follow-up component in a random subset of 7,519 patients.
For all patients, a comprehensive standardised clinical
evaluation (patients’ self-report and physicians’ assess-
ments) was conducted. Patients in the prospective subset
were additionally characterised by an extensive standard-
ised laboratory programme. The main target of the
DETECT study was the assessment of cardiovascular risk.
Assessment of comorbidities, biochemical variables
and covariates
Clinical characteristics of the subjects were collected with
regard to disease history, tumour characteristics, previous
and current therapy, and comorbidities as well as current
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123complaints. Comorbidities were diagnosed based on the
physicians’ assessments according to respective guidelines.
In the case of missing data or uncertainty, additional
information was obtained by ﬁle review. Biochemical
control in acromegalic patients was deﬁned as (a) GH
below 1 lg/L during a glucose tolerance test over 2 h, or
(b) age- and gender-adjusted normal values for IGF-1
within two standard deviations [16].
Regarding measurement of biochemical variables,
serum concentrations of GH were measured using the
automated Advantage chemiluminescent assay system
(Nichols Diagnostics Institute, Bad Vilbel, Germany), and
IGF-1 was determined on the continuous random access
analyzer Immulite
 2000 IGF-1 (Fa. DPC). Fasting plasma
glucose and HbA1c were determined using the GLU and
HBA1C II system of Roche, respectively. Cholesterol and
triglycerides were also determined on a Roche analyser
(CHOL, TG). Lipoproteins HDL and LDL were deter-
mined using the Roche HDL-C plus 3rd generation and
LDL-C plus 2nd generation assay, respectively. Lipopro-
tein (a) was determined by nephelometry.
Within the DETECT-study, blood samples were col-
lected and shipped by courier at room temperature within
24 h to the central laboratory (Medical University of Graz,
Austria). Upon arrival, the samples were centrifuged
immediately and serum and plasma were stored at 20C
until further processing. Clinical chemical parameters, as
well as cholesterol and triglycerides, were determined on a
Roche Modular automatic analyzer. Lipoproteins were
determined electrophoretically on the HEENA SAS-3/
SAS-4 system. HbA1c was determined chromatographi-
cally on an ADAMS HA 8160 analysing system.
Statistical analysis
The statistical analysis was performed using the software
package STATA 10.0 (Stata Corp). Statistical tests were
conducted by logistic regression models for categorical
variables and linear regression models for dimensional
variables. Standard errors were estimated by Taylor line-
arization to account for the dependent clustered data
structure.
Results
Demographic and clinical characteristics of the
acromegalic study group
The acromegalic group (n = 81) comprised of 43 female
(53.1%) and 38 male patients (46.9%) with a mean age of
54.7 ± 1.4 years. Patients with acromegaly had a high
prevalence of pituitary macroadenomas (65%). 73 patients
(90.1%) received transsphenoidal surgery as the primary
therapy; the mean time after surgery was 10.15 ±
0.88 years. 44 patients (54.3%) received medical treatment
including 10 patients (12.3%) currently under dopamine
agonists, 28 patients currently under somatostatin analogs
and 9 patients (11.1%) currently under pegvisomant. A
20 patients (24.7%) were irradiated, 10 patients (12.3%)
received Gammaknife, 1 patient (1.2%) Cyberknife and 5
patients (6.2%) stereotactic fractionated radiatio. The
mean time after radiotherapy was 9.1 ± 1.61 years. The
acromegalic patients often suffered from arthralgia
(65.4%), pituitary deﬁciency (59.3%), arterial hyperten-
sion (54.3%), carpal tunnel syndrome (45.7%), sleep
apnea (34.6%), diabetes mellitus (27.2%) and malignan-
cies (11.1%).
Acromegaly was biochemically controlled in 49 patients
(58%) at the time of study. The mean actual GH and IGF-I
SE scores were 2.8 ± 0.59 and 214.2 ± 18.0 lg/L,
respectively.
Comparisons of anthropometric parameters
and cardiovascular risk biomarkers between
all acromegalic patients and primary care controls
Table 1 summarises the results on anthropometric param-
eters and laboratory ﬁndings. The whole group of 81
acromegalic patients presented with signiﬁcantly higher
anthropometric parameters, such as weight, BMI, waist
and hip circumference, in comparison to their respective
controls (86.6 ± 17.8 vs. 79.8 ± 17.4 kg; P = 0.002;
29.2 ± 5.2 vs. 27.5 ± 5.6 kg/m
2; P = 0.014; 100.0 ±
14.3 vs. 95.7 ± 15.5 cm; P = 0.026; 110.6 ± 9.2 vs.
105.6 ± 12.0 cm; P = 0.001, respectively).
Additionally, cardiovascular risk biomarkers, such as
fasting plasma glucose, total cholesterol, triglycerides
and HDL levels, were more favourable in the acrome-
galic group compared to the age- and gender-matched
controls.
Regarding comorbidities, acromegalic patients suffered
signiﬁcantly more often from hypertension (54.3 vs.
37.8%; P = 0.008) and malignancies (11.1 vs. 3.1%;
P = 0.005), but less often from myocardial infarction (1.2
vs. 36.7%; P = 0.001), compared to their respective con-
trols. In detail, the malignancies reported included two
patients with skin cancer, one patient with colorectal car-
cinoma, one patient with renal carcinoma, one patient with
thyroid carcinoma, one patient with cervical carcinoma,
one patient with breast cancer, one patient with both breast
and skin cancer and one patient with an unknown
malignancy.
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and cardiovascular risk biomarkers between
biochemically cured and uncontrolled patients
and respective non-acromegalic controls
We went onto stratify the study group into controlled and
uncontrolled patients and compared them to their respec-
tive primary care control patients.
When evaluating biochemically controlled acromegalic
patientsincomparisontotheirrespectiveDETECTcontrols,
anthropometric measurements such as weight (85.6 ±
17.9 vs. 78.5 ± 18.5 kg; P = 0.015), BMI (29.5 ± 5.9
vs. 27.3 ± 5.8 kg/m
2; P = 0.020), waist (100.9 ± 16.8
vs. 94.8 ± 15.5 cm; P = 0.031) and hip circumference
(110.7 ± 9.9 vs. 105.0 ± 11.7 cm; P = 0.001) were
signiﬁcantly higher in biochemically controlled patients.
Cardiovascular risk biomarkers, such as fasting plasma
glucose (90.9 ± 16.7 vs. 104.8 ± 39.3 mg/dL; P = 0.000)
and triglycerides (118.5 ± 59.4 vs. 153.8 ± 123.1 mg/dL;
P = 0.006), were signiﬁcantly lower in biochemically
controlled patients. Since radiation might also play a role in
causing pituitary deﬁciency with effects on both body
composition and cardiovascular risk biomarkers, we also
performed the same analyses excluding patients who had
been irradiated or were pituitary-deﬁcient. We observed
similar resultswith signiﬁcantdifferencesinBMI,waistand
hip circumference between the groups (P = 0.039, 0.015
and 0.001, respectively).
Table 1 Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between patients with acromegaly
(n = 81) and the age- and gender-matched DETECT-controls (n = 320)
Patients with acromegaly (n = 81) DETECT-control group (n = 320) P-value
n % n %
Comorbidities
Hypertension 44 54.3 121 37.8 0.008
Diabetes mellitus 22 27.2 58 18.1 0.073
Coronary heart disease 7 8.6 30 9.4 0.840
Myocardial infarction 1 1.2 11 36.7 0.001
Cerebral insult 4 4.9 0 0.0 –
Malignancies 9 11.1 10 3.1 0.005
Pituitary deﬁciency 48 59.3
Corticotrope deﬁciency 35 43.2
Thyreotrope deﬁciency 22 27.2
Gonadotrope deﬁciency 33 40.7
Growth hormone deﬁciency 3 3.7
Mean (SD) Mean (SD) P-value
Anthropometric parameters
Height (cm) 172.4 (12.0) 170.1 (9.3) 0.107
Weight (kg) 86.6 (17.8) 79.8 (17.4) 0.002
BMI (kg/m
2) 29.2 (5.2) 27.5 (5.6) 0.014
Waist circumference (cm) 100.0 (14.3) 95.7 (15.5) 0.026
Hip circumference (cm) 110.6 (9.2) 105.6 (12.0) 0.001
Waist to height ratio 0.58 (0.09) 0.56 (0.09) 0.174
Biochemical parameters
IGF-1 (lg/L) 214.2 (161.2) 131.5 (54.3) 0.000
Cardiovascular risk biomarkers
Fasting plasma glucose (mg/dL) 93.5 (16.5) 104.1 (35.1) 0.001
HbA1c (%) 5.7 (0.5) 5.6 (1.0) 0.550
Total cholesterol (mg/dL) 215.8 (39.5) 226.6 (44.0) 0.045
Triglycerides (mg/dL) 121.1 (63.6) 160.8 (155.3) 0.001
HDL (mg/dL) 60.4 (21.4) 53.0 (17.6) 0.009
LDL (mg/dL) 139.4 (37.4) 131.0 (32.4) 0.093
Lipoprotein (a) (mg/dL) 36.1 (43.5) 33.3 (47.3) 0.707
Note: Signiﬁcant effects are bold typed
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remained between uncontrolled acromegalic patients and
their controls after stratiﬁcation, indicating that the
observed differences between the acromegalic and the
control group can be fully attributed to the controlled
acromegalic patient group (Table 2).
In order to exclude type 2 diabetes mellitus as a
potential inﬂuence on our calculations, we performed fur-
ther stratiﬁed analyses with acromegalic patients and pri-
mary care controls, with and without the diagnosis of type
2 diabetes mellitus.
Comparisons of patients with acromegaly with
and without diabetes mellitus and the respective
primary care controls
Twenty-two acromegalic subjects were diagnosed with
diabetes mellitus (age- and gender-matched control group
of patients with diabetes mellitus n = 88) during the
course of the disease or treatment; 12 patients with acro-
megaly and diabetes mellitus had been treated with dopa-
mine agonists, 12 with the somatostatin analogue
octreotide, 5 with lanreotide and 4 with the GH receptor
Table 2 Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between biochemically controlled
(n = 49) and uncontrolled patients (n = 31) and the age- and gender-matched DETECT-controls (n = 196 and n = 120, respectively)
Patients with
uncontrolled
acromegaly
(n = 31)
Patients with
controlled
acromegaly
(n = 49)
P-value controlled
versus uncontrolled
acromegaly
DETECT-control
group, patients
with uncontrolled
acromegaly
(n = 120)
P-value versus
uncontrolled
acromegaly
DETECT-
control group,
patients with
controlled
acromegaly
(n = 196)
P-value versus
controlled
acromegaly
n % n % n % n %
Comorbidities
Hypertension 16 51.6 27 55.1 0.762 46 38.3 0.191 75 38.3 0.037
Diabetes
mellitus
7 22.6 15 30.6 0.438 23 19.2 0.676 35 17.9 0.049
Coronary
heart disease
4 12.9 3 6.1 0.309 11 9.2 0.544 19 9.7 0.443
Myocardial
infarction
0 0.0 1 2.0 – 4 36.4 – 7 36.8 0.001
Cerebral
insult
0 0.0 4 8.2 – 0 0.0 – 0 0.0 –
Malignancies 5 16.1 4 8.2 0.283 5 4.2 0.029 5 2.6 0.080
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Anthropometric parameters
Height (cm) 174.5 (13.5) 170.7 (10.6) 0.188 170.9 (9.9) 0.165 169.3 (8.7) 0.391
Weight (kg) 87.1 (17.2) 85.6 (17.9) 0.707 81.4 (15.4) 0.101 78.5 (18.5) 0.015
BMI (kg/m
2) 28.5 (4.0) 29.5 (5.9) 0.376 27.9 (5.2) 0.523 27.3 (5.8) 0.020
Waist circumference (cm) 98.2 (9.8) 100.9 (16.8) 0.384 97.0 (15.6) 0.606 94.8 (15.5) 0.031
Hip circumference (cm) 109.9 (7.4) 110.7 (9.9) 0.719 106.5 (12.6) 0.063 105.0 (11.7) 0.001
Waist to height ratio 0.56 (0.06) 0.59 (0.10) 0.190 0.57 (0.09) 0.712 0.56 (0.09) 0.089
Biochemical parameters
IGF-1 (lg/L) 317.1 (216.7) 149.1 (47.7) 0.000 135.5 (52.5) 0.000 128.7 (55.5) 0.011
Cardiovascular risk biomarkers
Fasting plasma glucose (mg/dL) 97.5 (15.9) 90.9 (16.7) 0.084 103.7 (27.3) 0.107 104.8 (39.3) 0.000
HbA1c (%) 5.8 (0.5) 5.6 (0.4) 0.104 5.6 (0.9) 0.069 5.7 (1.1) 0.566
Total cholesterol (mg/dL) 204.6 (42.1) 223.6 (36.8) 0.058 225.0 (38.3) 0.022 227.7 (47.6) 0.534
Triglycerides (mg/dL) 118.2 (62.3) 118.5 (59.4) 0.987 174.4 (198.5) 0.011 153.8 (123.1) 0.006
HDL (mg/dL) 62.2 (24.8) 60.0 (19.2) 0.702 51.2 (17.5) 0.040 54.1 (17.6) 0.077
LDL (mg/dL) 128.8 (40.1) 146.9 (34.2) 0.070 129.6 (28.5) 0.929 131.9 (34.8) 0.013
Lipoprotein (a) (mg/dL) 40.3 (48.6) 34.1 (41.7) 0.706 32.3 (43.4) 0.585 34.0 (49.9) 0.985
Note: Signiﬁcant effects are bold typed
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possible).
As presented in Table 3, we did not see signiﬁcant
differences in anthropometric parameters between acro-
megalic patients with diabetes mellitus and controls with
diabetes mellitus. Additionally, the acromegalic patient
group with diabetes mellitus even displayed an improved
cardiovascular risk proﬁle regarding HDL (61.7 ± 20.8
vs. 53.3 ± 16.5 mg/dL; P = 0.010) and lipoprotein (a)
levels (13.8 ± 8.5 vs. 37.6 ± 54.7 mg/dL; P = 0.021), but
not regarding total cholesterol, triglycerides and LDL.
Acromegalic patients without diabetes mellitus presented
signiﬁcantly more often with hypertension (49.2 vs.
37.9%; P = 0.007), but with lower fasting plasma glu-
cose (89.9 ± 11.9 vs. 104.3 ± 36.8 mg/dL; P = 0.011),
total cholesterol (214.3 ± 39.0 vs. 227.1 ± 45.9 mg/dL;
P = 0.031) and triglycerides levels (107.1 ± 54.4 vs.
158.8 ± 128.2 mg/dL; P = 0.000) compared to their
respective controls.
Discussion
This study demonstrates that biochemically cured acro-
megalic patients exhibit an adverse anthropometric risk
proﬁle compared to an age- and gender-matched primary
care control cohort.
Various factors could explain our reported ﬁndings. One
possible reason for the adverse anthropometric measure-
ments might be a relative ‘‘overtreatment of acromegaly’’
resulting in subsequent symptoms of relative growth hor-
mone deﬁciency. However, in our study only three
Table 3 Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between acromegalic patients with
(n = 22) and without diabetes mellitus (n = 59) and the age- and gender-matched DETECT-controls (n = 88 and n = 232, respectively)
Patients with
acromegaly
and no diabetes
mellitus ? (n = 59)
Patients with
acromegaly and
diabetes mellitus
(n = 22)
P-value no
diabetes
versus
diabetes
DETECT-control
group, patients
with no diabetes
(n = 232)
P-value
versus no
diabetes
DETECT-control
group, patients
with diabetes
(n = 88)
P-value
versus
diabetes
n % n % n % n %
Comorbidities
Hypertension 29 49.2 15 68.2 0.133 88 37.9 0.007 33 37.5 0.715
Diabetes mellitus – – – – 42 18.1 – 16 18.2 –
Coronary heart disease 5 8.5 2 9.1 0.930 24 10.3 0.437 6 6.8 0.130
Myocardial infarction 1 1.7 0 0.0 – 7 29.2 0.002 4 66.7 –
Cerebral insult 1 1.7 3 13.6 0.063 0 0.0 – 0 0.0 –
Malignancies 6 10.2 3 13.6 0.662 7 3.0 0.015 3 3.4 0.227
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Anthropometric parameters
Height (cm) 174.7 (12.1) 166.0 (9.1) 0.001 171.1 (9.2) 0.006 167.3 (9.0) 0.060
Weight (kg) 87.3 (17.7) 84.6 (18.6) 0.559 80.5 (17.1) 0.000 77.7 (18.2) 0.449
BMI (kg/m
2) 28.6 (4.8) 30.7 (6.2) 0.155 27.5 (5.3) 0.015 27.6 (6.1) 0.831
Waist circumference (cm) 98.9 (10.9) 102.8 (21.4) 0.449 96.3 (15.9) 0.003 93.8 (14.3) 0.596
Hip circumference (cm) 110.8 (8.7) 110.2 (10.7) 0.830 105.6 (12.1) 0.000 105.6 (11.9) 0.829
Waist to height ratio 0.57 (0.06) 0.61 (0.13) 0.131 0.56 (0.09) 0.127 0.56 (0.08) 0.870
Biochemical parameters
IGF-1 (lg/L) 218.6 (152.6) 202.7 (185.5) 0.720 135.4 (56.2) 0.000 121.4 (48.0) 0.057
Cardiovascular risk biomarkers
Fasting plasma glucose (mg/dL) 89.9 (11.9) 103.6 (22.8) 0.010 104.3 (36.8) 0.011 103.5 (30.2) 0.000
HbA1c (%) 5.6 (0.4) 5.9 (0.6) 0.038 5.6 (1.0) 0.000 5.7 (0.9) 0.000
Total cholesterol (mg/dL) 214.3 (39.0) 219.8 (41.7) 0.616 227.1 (45.9) 0.031 225.3 (38.9) 0.787
Triglycerides (mg/dL) 107.1 (54.4) 157.3 (72.5) 0.007 158.8 (128.2) 0.000 166.2 (211.8) 0.071
HDL (mg/dL) 59.9 (21.8) 61.7 (20.8) 0.748 52.9 (18.0) 0.095 53.3 (16.5) 0.010
LDL (mg/dL) 139.7 (37.0) 138.7 (39.4) 0.920 131.4 (33.5) 0.195 130.2 (29.4) 0.209
Lipoprotein (a) (mg/dL) 45.6 (48.8) 13.8 (8.5) 0.003 31.6 (44.3) 0.282 37.6 (54.7) 0.021
Note: Signiﬁcant effects are bold typed
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123biochemically cured acromegalic patients had a low IGF-1
below two standard deviations as a potential marker of rel-
ative growth hormone deﬁciency, which is not sufﬁcient to
fully account for the observed effect.
Other pituitary deﬁciencies also might explain our ﬁnd-
ings, as suggested by Schmid et al. The authors found an
increased prevalence of high BMI in patients with pituitary
tumours, possibly caused by partial pituitary failure [17]. In
our patient sample, 48 patients (59.3%) suffered from pitu-
itary deﬁciencies in total, and 19 patients (23.5%) received
hormonal replacement therapy with hydrocortisone. Inade-
quate dosages or overtreatment could have caused the
adverse anthropometric proﬁle in these patients.
Another factor could be that acromegalic patients lack
physical exercise because of persisting joint complaints or
arthropathy,asreportedbyBiermaszetal.[18].Asarthralgia
was reported by 65.4% of the patients in this cohort, this
might have contributed greatly to the observed effect [19].
Additionally, the medical treatment itself might lead to
the increased measurements for body mass and body fat.
Plo ¨ckinger et al. [20], for instance, proposed a signiﬁcant
increase in intra-abdominal fat mass during therapy with the
GH receptor antagonist pegvisomant, while subcutaneous
fatwasnotsigniﬁcantlydifferent.Inthisacromegaliccohort,
the signiﬁcant number of nine patients (11%) were being
treated with pegvisomant at the time of study which might
explain a large proportion of the observed results.
As a limitation of our study, we have to consider that the
measurements reported here are restricted to anthropo-
metric parameters without direct measurements of lean
tissue mass or fat mass, since a DEXA measurement or
other more site-speciﬁc measurements were not part of the
DETECT study. On the other hand, anthropometric mea-
surements alone are already strong indicators for morbidity
and mortality, as published by Schneider et al. [21]. We
therefore believe that they should be sufﬁciently valid.
We can only speculate as to why some cardiovascular
risk biomarkers, such as triglycerides, are more favourable
than in the control group. One possible explanation could
be that acromegalic patients are more aggressively treated
than the control group with, i.e., a lipid lowering therapy,
because of the known cardiovascular risk proﬁle. However,
we did not analyse this systematically.
Furthermore, some measurements in acromegalic
patients versus DETECT subjects had to be performed with
different laboratory methods, possibly yielding systematic
differences and inﬂuencing our ﬁndings. However, both
laboratories are part of routine standardisation procedures
and should therefore deliver comparable results. Addi-
tionally, most of the examined biochemical parameters
were measured with the same assays.
Moreover, cardiovascular risk biomarkers are only
markers and the study was not designed to analyse ‘‘hard’’
end points, such as incidence of hypertension, myocardial
infarction or stroke.
We also have to consider that we are comparing to a
primary care patient population which is not representative
for the general population, since primary care patients can
be expected to be less healthy than the general population.
Nevertheless, we believe that the selection of the control
group represents a valid comparison because it contrasts to
a group that seeks medical advice for other reasons,
reﬂecting a realistic scenario.
How the reported ﬁndings might inﬂuence the current
management paradigm of acromegaly is not clear. How-
ever, stricter treatment goals of cardiovascular risk factors
targeting mainly overweight and visceral adiposity in these
patients are likely to be beneﬁcial.
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